OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Current advances of small molecule E3 ligands for proteolysis-targeting chimeras design
Dazhao Mi, Yuzhan Li, Haijun Gu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 256, pp. 115444-115444
Closed Access | Times Cited: 27
Dazhao Mi, Yuzhan Li, Haijun Gu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 256, pp. 115444-115444
Closed Access | Times Cited: 27
Showing 1-25 of 27 citing articles:
Current advances and development strategies of orally bioavailable PROTACs
Shenxin Zeng, Yingqiao Ye, Heye Xia, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115793-115793
Closed Access | Times Cited: 35
Shenxin Zeng, Yingqiao Ye, Heye Xia, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115793-115793
Closed Access | Times Cited: 35
Targeted protein degradation: advances in drug discovery and clinical practice
Guangcai Zhong, Xiaoyu Chang, Weilin Xie, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 13
Guangcai Zhong, Xiaoyu Chang, Weilin Xie, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 13
Discovery of Effective Dual PROTAC Degraders for Neurodegenerative Disease-Associated Aggregates
Wentao Zhu, Wenqian Zhang, Jian Chen, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 5, pp. 3448-3466
Closed Access | Times Cited: 12
Wentao Zhu, Wenqian Zhang, Jian Chen, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 5, pp. 3448-3466
Closed Access | Times Cited: 12
Restraining the power of Proteolysis Targeting Chimeras in the cage: A necessary and important refinement for therapeutic safety
Renshuai Zhang, Songbo Xie, Jie Ran, et al.
Journal of Cellular Physiology (2024) Vol. 239, Iss. 5
Closed Access | Times Cited: 10
Renshuai Zhang, Songbo Xie, Jie Ran, et al.
Journal of Cellular Physiology (2024) Vol. 239, Iss. 5
Closed Access | Times Cited: 10
Alkenyl oxindole is a novel PROTAC moiety that recruits the CRL4DCAF11 E3 ubiquitin ligase complex for targeted protein degradation
Ying Wang, Tianzi Wei, Man Zhao, et al.
PLoS Biology (2024) Vol. 22, Iss. 5, pp. e3002550-e3002550
Open Access | Times Cited: 8
Ying Wang, Tianzi Wei, Man Zhao, et al.
PLoS Biology (2024) Vol. 22, Iss. 5, pp. e3002550-e3002550
Open Access | Times Cited: 8
Proteomic approaches advancing targeted protein degradation
Gajanan Sathe, Gopal P. Sapkota
Trends in Pharmacological Sciences (2023) Vol. 44, Iss. 11, pp. 786-801
Open Access | Times Cited: 21
Gajanan Sathe, Gopal P. Sapkota
Trends in Pharmacological Sciences (2023) Vol. 44, Iss. 11, pp. 786-801
Open Access | Times Cited: 21
Accelerating PROTACs Discovery Through a Direct‐to‐Biology Platform Enabled by Modular Photoclick Chemistry
Ke‐Nian Yan, Yong‐Qiang Nie, Jiayu Wang, et al.
Advanced Science (2024) Vol. 11, Iss. 26
Open Access | Times Cited: 7
Ke‐Nian Yan, Yong‐Qiang Nie, Jiayu Wang, et al.
Advanced Science (2024) Vol. 11, Iss. 26
Open Access | Times Cited: 7
Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders
Nisha Setia, Haider Thaer Abdulhameed Almuqdadi, Mohammad Abid
European Journal of Medicinal Chemistry (2023) Vol. 265, pp. 116041-116041
Closed Access | Times Cited: 14
Nisha Setia, Haider Thaer Abdulhameed Almuqdadi, Mohammad Abid
European Journal of Medicinal Chemistry (2023) Vol. 265, pp. 116041-116041
Closed Access | Times Cited: 14
Clozapine as an E3 Ligand for PROTAC Technology
Reina Takano, Nobumichi Ohoka, Takashi Kurohara, et al.
ACS Medicinal Chemistry Letters (2025) Vol. 16, Iss. 2, pp. 258-262
Closed Access
Reina Takano, Nobumichi Ohoka, Takashi Kurohara, et al.
ACS Medicinal Chemistry Letters (2025) Vol. 16, Iss. 2, pp. 258-262
Closed Access
Unleashing the Power of Covalent Drugs for Protein Degradation
Meng‐Jie Fu, Hang Jin, Shao‐Peng Wang, et al.
Medicinal Research Reviews (2025)
Closed Access
Meng‐Jie Fu, Hang Jin, Shao‐Peng Wang, et al.
Medicinal Research Reviews (2025)
Closed Access
Structural Optimization and Characterization of Highly Potent and Selective STAT3 Inhibitors for the Treatment of Triple Negative Breast Cancer
Wangrui Jin, Yuzhu Zhang, Baozhen Wang, et al.
European Journal of Medicinal Chemistry (2025) Vol. 287, pp. 117332-117332
Closed Access
Wangrui Jin, Yuzhu Zhang, Baozhen Wang, et al.
European Journal of Medicinal Chemistry (2025) Vol. 287, pp. 117332-117332
Closed Access
Nonclinical teratogenicity safety assessment of CRBN-engaging targeted protein degraders: Points to consider
Lise I. Loberg, William R Proctor, Andrew D. Burdick, et al.
Regulatory Toxicology and Pharmacology (2025), pp. 105793-105793
Closed Access
Lise I. Loberg, William R Proctor, Andrew D. Burdick, et al.
Regulatory Toxicology and Pharmacology (2025), pp. 105793-105793
Closed Access
Target protein degradation by protacs: A budding cancer treatment strategy
Diksha Choudhary, Amritpal Kaur, Pargat Singh, et al.
Pharmacology & Therapeutics (2023) Vol. 250, pp. 108525-108525
Closed Access | Times Cited: 12
Diksha Choudhary, Amritpal Kaur, Pargat Singh, et al.
Pharmacology & Therapeutics (2023) Vol. 250, pp. 108525-108525
Closed Access | Times Cited: 12
Recent advances in small molecule and peptide inhibitors of glucose-regulated protein 78 for cancer therapy
Weikai Guo, Manjie Wang, Zhengfan Yang, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115792-115792
Closed Access | Times Cited: 11
Weikai Guo, Manjie Wang, Zhengfan Yang, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115792-115792
Closed Access | Times Cited: 11
Discovery of novel BCL6-Targeting PROTACs with effective antitumor activities against DLBCL in vitro and in vivo
Dazhao Mi, Li Cheng, Yuzhan Li, et al.
European Journal of Medicinal Chemistry (2024) Vol. 277, pp. 116789-116789
Closed Access | Times Cited: 4
Dazhao Mi, Li Cheng, Yuzhan Li, et al.
European Journal of Medicinal Chemistry (2024) Vol. 277, pp. 116789-116789
Closed Access | Times Cited: 4
Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer
Yaxun Guo, Yuzhan Li, Zhongmei Zhou, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 2
Yaxun Guo, Yuzhan Li, Zhongmei Zhou, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 2
To homeostasis and beyond! Recent advances in the medicinal chemistry of heterobifunctional derivatives
Diana Castagna, Benoit Gourdet, Roland Hjerpe, et al.
Progress in medicinal chemistry (2024), pp. 61-160
Closed Access | Times Cited: 1
Diana Castagna, Benoit Gourdet, Roland Hjerpe, et al.
Progress in medicinal chemistry (2024), pp. 61-160
Closed Access | Times Cited: 1
Discovery of Alkenyl Oxindole as a Novel PROTAC Moiety for Targeted Protein Degradation via CRL4DCAF11Recruitment
Ying Wanga, Tianzi Wei, Man Zhao, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Ying Wanga, Tianzi Wei, Man Zhao, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Discovery of an efficacious KDM5B PROTAC degrader GT-653 up-regulating IFN response genes in prostate cancer
Tian Guan, Yingshuang Zhang, Li Shen, et al.
European Journal of Medicinal Chemistry (2024) Vol. 272, pp. 116494-116494
Closed Access | Times Cited: 1
Tian Guan, Yingshuang Zhang, Li Shen, et al.
European Journal of Medicinal Chemistry (2024) Vol. 272, pp. 116494-116494
Closed Access | Times Cited: 1
PROteolysis‐Targeting Chimeras (PROTACs) in leukemia: overview and future perspectives
André T. S. Vicente, Jorge A. R. Salvador
MedComm (2024) Vol. 5, Iss. 6
Open Access | Times Cited: 1
André T. S. Vicente, Jorge A. R. Salvador
MedComm (2024) Vol. 5, Iss. 6
Open Access | Times Cited: 1
Application of Fluorescence- and Bioluminescence-Based Biosensors in Cancer Drug Discovery
Tynan Kelly, Xiaolong Yang
Biosensors (2024) Vol. 14, Iss. 12, pp. 570-570
Open Access | Times Cited: 1
Tynan Kelly, Xiaolong Yang
Biosensors (2024) Vol. 14, Iss. 12, pp. 570-570
Open Access | Times Cited: 1
Preparation of von Hippel-Lindau (VHL) E3 ubiquitin ligase ligands exploiting constitutive hydroxyproline for benzylic amine protection
Diana M. Soto-Martínez, Garrett D. Clements, John E. Díaz, et al.
RSC Advances (2024) Vol. 14, Iss. 24, pp. 17077-17090
Open Access
Diana M. Soto-Martínez, Garrett D. Clements, John E. Díaz, et al.
RSC Advances (2024) Vol. 14, Iss. 24, pp. 17077-17090
Open Access
A long march for targeted protein degradation in the new era: expanding E3 ligases
Dazhao Mi, A.D. Huang, Song Jingfeng, et al.
Future Medicinal Chemistry (2024), pp. 1-3
Open Access
Dazhao Mi, A.D. Huang, Song Jingfeng, et al.
Future Medicinal Chemistry (2024), pp. 1-3
Open Access
Fragment-based approaches to discover ligands for tumor-specific E3 ligases
Junhyeong Yim, S S Kim, Hyung Ho Lee, et al.
Expert Opinion on Drug Discovery (2024), pp. 1-14
Closed Access
Junhyeong Yim, S S Kim, Hyung Ho Lee, et al.
Expert Opinion on Drug Discovery (2024), pp. 1-14
Closed Access
PROTACs in platelets: emerging antithrombotic strategies and future perspectives
Justin S. Trory, Jordan Vautrinot, Carl May, et al.
Current Opinion in Hematology (2024)
Closed Access
Justin S. Trory, Jordan Vautrinot, Carl May, et al.
Current Opinion in Hematology (2024)
Closed Access
